medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2014, Number 4

<< Back Next >>

Rev Invest Clin 2014; 66 (4)

Poor performance of the total kappa/lambda light chain quantification in the diagnosis and follow-up of patients with multiple myeloma

Zamora-Ortiz G, Velázquez-Sánchez-de-Cima S, Hernández-Reyes J, Martagón-Herrera NA, Ruiz-Argüelles A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ

Language: English
References: 13
Page: 314-318
PDF size: 136.38 Kb.


ABSTRACT

Background. The gold standard for paraproteinemia screening in plasma cell disorders has been serum protein electrophoresis (SPE) with immunofixation electrophoresis (IFx); serum total and free light chain quantifications have also been used. Objective. To define the role of SPE, IFx and serum total light chain (sLC) determinations in patients with multiple myeloma (MM), both at diagnosis and at maximum response during treatment follow-up. Material and methods. These serological studies were performed in a group of 62 patients with MM at diagnosis, and in a subset of 29 patients at the point of maximum response to treatment. Results. At diagnosis, we found an abnormal SPE in 58%, an abnormal IFx in 92% and an abnormal sLC in 45% of the 62 patients; 64% had simultaneously abnormal results in all three serological studies. IFx alone proved to be the most sensitive of all three assays, followed by SPE, which was redundant in most instances with sLC and IFx. At maximum response, the abnormal SPE normalized in 7 cases, the abnormal IFx in 7 cases and the abnormal sLC in 7 cases. There were 12 instances in which an abnormal IFx was found despite normal sLC, and one case in which a normal IFx was found in the presence of abnormal sLC. The association between IFx and sLC was highly significant (r = 0.9274611, p ‹ 0.000001), despite instances where a positive result for IFx was associated to a normal sLC. Conclusions. All three serological methods should ideally be simultaneously performed in patients with MM both at diagnosis and throughout therapy. In this series, the total sLC assay was not more sensitive than IFx neither at diagnosis nor during follow-up.


REFERENCES

  1. Hernández-Reyes J, Galo-Hooker E, Ruiz-Delgado GJ, Ruiz- Argüelles GJ. Systemic immunoglobulin light-chain amyloidosis (AL) in México: A single institution, 30-year experience. Rev Invest Clin 2012; 64: 604-08.

  2. Ruiz-Delgado GJ, Gómez-Rangel D. Gamopatía monoclonal de significado indeterminado en mestizos mexicanos: experiencia de una sola institución. Gac Med Mex 2004; 140(4): 375-9.

  3. Ruiz-Delgado GJ, Ruiz-Argüelles GJ. Genetic predisposition for monoclonal gammopathy of undetermined significance. Mayo Clin Proc 2008; 83: 601-03.

  4. Ruiz-Argüelles GJ, Ruiz-Delgado GJ. On the prevalence and genetic predisposition of monoclonal gammopathy of undetermined significance (MGUS). Int J Hematol 2012; 96: 144-5.

  5. Ruiz-Argüelles GJ, Gómez-Rangel D, Ruiz-Delgado GJ, Aguilar-Romero L. Multiple myeloma in Mexico: a 20-year experience at a single institution. Arch Med Res 2004; 35: 163-7.

  6. Ruiz-Argüelles GJ, Ramírez-Cisneros FJ, Flores-Martínez J, Cernuda-Graham MC. Waldenstrom’s macroglobulinemia is infrequent in Mexican Mestizos: experience of a hematological diseases referral center. Rev Invest Clin 2000; 52: 497-9.

  7. Dispenzieri A, Kyle RA, Merlini G, San-Miguel JF, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215-24.

  8. Alper CA. Plasma protein measurements as a diagnostic aid. N Engl J Med 1974; 291: 287-90.

  9. Ritchie RF, Smith R. Immunofixation III. Application to the study of monoclonal proteins. Clin Chem 1976; 22: 1982-5.

  10. Lievens MM. Medical and technical usefulness of measurement of kappa and lambda immunoglobulin light chains in serum with an M component. J Clin Chem Clin Biochem 1989; 27: 519-23.

  11. Katzmann JA, Dispenzieri A, Kyle RA, Snyder MR, Plevak MF, Larson DR, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 2006; 81: 1575-8.

  12. Durie BG, Harousseau JL, San-Miguel JF, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-73.

  13. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006; 107: 3378-83.




2020     |     www.medigraphic.com